Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies
Molecular targeted therapy has revolutionized cancer treatment by significantly improving patient survival compared with standard conventional chemotherapies. The use of these drugs targets specific molecules or targets, which block growth and spread of cancer cells. Many of these therapies have bee...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer - Lippincott Williams & Wilkins
2024-11-01
|
| Series: | Kidney360 |
| Online Access: | http://journals.lww.com/10.34067/KID.0000000566 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235042311176192 |
|---|---|
| author | Jaya Kala Teresa Joseph Marta Pirovano Roberta Fenoglio Laura Cosmai |
| author_facet | Jaya Kala Teresa Joseph Marta Pirovano Roberta Fenoglio Laura Cosmai |
| author_sort | Jaya Kala |
| collection | DOAJ |
| description | Molecular targeted therapy has revolutionized cancer treatment by significantly improving patient survival compared with standard conventional chemotherapies. The use of these drugs targets specific molecules or targets, which block growth and spread of cancer cells. Many of these therapies have been approved for use with remarkable success in breast, blood, colorectal, lung, and ovarian cancers. The advantage over conventional chemotherapy is its ability to deliver drugs effectively with high specificity while being less toxic. Although known as “targeted,” many of these agents lack specificity and selectivity, and they tend to inhibit multiple targets, including those in the kidneys. The side effects usually arise because of dysregulation of targets of the inhibited molecule in normal tissue. The off-target effects are caused by drug binding to unintended targets. The on-target effects are associated with inhibition toward the pathway reflecting inappropriate inhibition or activation of the intended drug target. Early detection and correct management of kidney toxicities is crucial to preserve kidney functions. The knowledge of these toxicities helps guide optimal and continued utilization of these potent therapies. This review summarizes the different types of molecular targeted therapies used in the treatment of cancer and the incidence, severity, and pattern of nephrotoxicity caused by them, with their plausible mechanism and proposed treatment recommendations. |
| format | Article |
| id | doaj-art-c0427ac24d844c96827b2784a797b521 |
| institution | OA Journals |
| issn | 2641-7650 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wolters Kluwer - Lippincott Williams & Wilkins |
| record_format | Article |
| series | Kidney360 |
| spelling | doaj-art-c0427ac24d844c96827b2784a797b5212025-08-20T02:02:25ZengWolters Kluwer - Lippincott Williams & WilkinsKidney3602641-76502024-11-015111750176210.34067/KID.0000000566202411000-00022Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted TherapiesJaya Kala0Teresa Joseph1Marta Pirovano2Roberta Fenoglio3Laura Cosmai41 Division of Nephrology, Department of Internal Medicine, University of Texas Health Science Center-McGovern Medical School, Houston, Texas1 Division of Nephrology, Department of Internal Medicine, University of Texas Health Science Center-McGovern Medical School, Houston, Texas3 Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy5 University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Turin, Italy8 Onconephrology Outpatient Clinic, Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milan, ItalyMolecular targeted therapy has revolutionized cancer treatment by significantly improving patient survival compared with standard conventional chemotherapies. The use of these drugs targets specific molecules or targets, which block growth and spread of cancer cells. Many of these therapies have been approved for use with remarkable success in breast, blood, colorectal, lung, and ovarian cancers. The advantage over conventional chemotherapy is its ability to deliver drugs effectively with high specificity while being less toxic. Although known as “targeted,” many of these agents lack specificity and selectivity, and they tend to inhibit multiple targets, including those in the kidneys. The side effects usually arise because of dysregulation of targets of the inhibited molecule in normal tissue. The off-target effects are caused by drug binding to unintended targets. The on-target effects are associated with inhibition toward the pathway reflecting inappropriate inhibition or activation of the intended drug target. Early detection and correct management of kidney toxicities is crucial to preserve kidney functions. The knowledge of these toxicities helps guide optimal and continued utilization of these potent therapies. This review summarizes the different types of molecular targeted therapies used in the treatment of cancer and the incidence, severity, and pattern of nephrotoxicity caused by them, with their plausible mechanism and proposed treatment recommendations.http://journals.lww.com/10.34067/KID.0000000566 |
| spellingShingle | Jaya Kala Teresa Joseph Marta Pirovano Roberta Fenoglio Laura Cosmai Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies Kidney360 |
| title | Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies |
| title_full | Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies |
| title_fullStr | Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies |
| title_full_unstemmed | Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies |
| title_short | Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies |
| title_sort | acute kidney injury associated with anticancer therapies small molecules and targeted therapies |
| url | http://journals.lww.com/10.34067/KID.0000000566 |
| work_keys_str_mv | AT jayakala acutekidneyinjuryassociatedwithanticancertherapiessmallmoleculesandtargetedtherapies AT teresajoseph acutekidneyinjuryassociatedwithanticancertherapiessmallmoleculesandtargetedtherapies AT martapirovano acutekidneyinjuryassociatedwithanticancertherapiessmallmoleculesandtargetedtherapies AT robertafenoglio acutekidneyinjuryassociatedwithanticancertherapiessmallmoleculesandtargetedtherapies AT lauracosmai acutekidneyinjuryassociatedwithanticancertherapiessmallmoleculesandtargetedtherapies |